Drug Profile
Etoposide toniribate - Mundipharma
Alternative Names: CAP-7.1Latest Information Update: 31 Jul 2019
Price :
$50
*
At a glance
- Originator Institute for Medical Immunology Charite - Universitatsmedizin Berlin
- Developer CellAct Pharma; Mundipharma EDO
- Class Antineoplastics; Naphthols; Small molecules
- Mechanism of Action Carbonic anhydrase stimulants; DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Biliary cancer
- No development reported Non-small cell lung cancer; Small cell lung cancer
Most Recent Events
- 31 Jul 2019 Etoposide toniribate is still in phase II trials for Biliary cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany
- 31 Jul 2019 No development reported - Phase-II for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (IV)
- 31 Jul 2019 No development reported - Phase-II for Small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (IV)